Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Search Results to David B Badesch

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Badesch, David

Item TypeName
Academic Article Bosentan therapy for pulmonary arterial hypertension.
Academic Article Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study.
Academic Article Survival with first-line bosentan in patients with primary pulmonary hypertension.
Academic Article Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.
Academic Article Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
Academic Article Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.
Academic Article Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.
Academic Article Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.
Concept Sulfonamides
Academic Article Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension.
Academic Article Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration.
Academic Article Reply: Perspectives on Oral Pulmonary Hypertension Therapies Recently Approved by the U.S. Food and Drug Administration.
Academic Article Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY Trial.

Search Criteria
  • Sulfonamides

Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)